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Pulmonary arterial hypertension (PAH) is a rare disorder with a poor prognosis. Deleterious 61 
variation within components of the transforming growth factor-β pathway, particularly the 62 
bone morphogenetic protein type 2 receptor (BMPR2), underlie most heritable forms of PAH. 63 
To identify the missing heritability we perform whole genome sequencing in 1038 PAH index 64 
cases and 6385 PAH-negative control subjects. Case-control analyses reveal significant 65 
overrepresentation of rare variants in ATP13A3, AQP1 and SOX17, and provide 66 
independent validation of a critical role for GDF2 in PAH. We demonstrate familial 67 
segregation of mutations in SOX17 and AQP1 with PAH. Mutations in GDF2, encoding a 68 
BMPR2 ligand, lead to reduced secretion from transfected cells. In addition, we identify 69 
pathogenic mutations in the majority of previously reported PAH genes, and provide 70 
evidence for further putative genes. Taken together these findings contribute new insights 71 
into the molecular basis of PAH and indicate unexplored pathways for therapeutic 72 




Idiopathic and heritable pulmonary arterial hypertension (PAH) are rare disorders 75 
characterised by occlusion of arterioles in the lung1, leading to marked increases in 76 
pulmonary vascular resistance2. Life expectancy from diagnosis averages 3-5 years3, with 77 
death ensuing from failure of the right ventricle. 78 
 79 
Mutations in the gene encoding the bone morphogenetic protein type 2 receptor (BMPR2), a 80 
receptor for the transforming growth factor-beta (TGF-β) superfamily4, 5 account for over 80% 81 
of families with PAH, and approximately 20% of sporadic cases6. Mutations have been 82 
identified in genes encoding other components of the TGF-β/bone morphogenetic protein 83 
(BMP) signalling pathways, including ACVRL17 and ENG8. On endothelial cells, BMPR2 and 84 
ACVRL1 form a signaling complex, utilizing ENG as a co-receptor. Case reports of rare 85 
sequence variation in the BMP signalling intermediaries, SMAD1, SMAD4 and SMAD99, 10, 86 
provide compelling evidence for a central role of dysregulated BMP signalling in PAH 87 
pathogenesis.  88 
 89 
Analysis of coding variation in BMPR2-negative kindreds revealed heterozygous mutations 90 
in genes not directly impacting on the TGF-β/BMP pathway, including CAV111, and the 91 
potassium channel, KCNK312. Deletions and loss of function mutations in TBX4, an essential 92 
regulator of embryonic development, were identified in childhood onset PAH13. A clinically 93 
and pathologically distinct form of PAH, known as pulmonary veno-occlusive disease or 94 
pulmonary capillary haemangiomatosis (PVOD/PCH), was shown recently to be caused by 95 
biallelic recessive mutations in EIF2AK414, 15, a kinase in the integrated stress response. 96 
 97 
The purpose of the present study was to identify additional rare sequence variation 98 
contributing to the genetic architecture of PAH, and to assess the relative contribution of rare 99 
variants in genes implicated in prior studies. A major finding is that rare likely causal 100 
heterozygous variants in several previously unidentified genes (ATP13A3, AQP1 and 101 
SOX17) were significantly overrepresented in the PAH cohort, and we provide independent 102 
validation for GDF2 as a causal gene.  103 
Results 104 
Description of the PAH cohort 105 
In total, 1048 PAH cases (1038 index cases and 10 related affected individuals) were 106 
recruited for WGS. Of these, 908 (86.7%) were diagnosed with idiopathic PAH, 58 (5.5%) 107 
gave a family history of PAH and 60 (5.7%) gave a history of drug exposure associated with 108 
PAH16. Twenty two cases (2.1%) held a clinical diagnosis of PVOD/PCH (Figure 1a). 109 
Demographic and clinical characteristics of the PAH cohort are provided in Supplementary 110 
Table 1. An additional UK family was recruited separately for novel gene identification 111 
studies. Briefly, the proband was diagnosed at 12 years with a persistent ductus arteriosus 112 
and elevated pulmonary arterial pressure. Explant lung histology following heart-lung 113 
transplantation revealed the presence of plexiform lesions. Two of the proband’s offspring 114 
were also diagnosed with childhood-onset PAH, one of which had an atrial septal defect. 115 
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The proband’s parents, siblings and a third child showed no evidence of cardiovascular 116 
disease. 117 
Pathogenic variants in previously reported PAH disease genes 118 
Our filtering strategy detected rare deleterious variation in previously reported PAH genes in 119 
19.9% of the PAH cohort. For BMPR2, rare heterozygous mutations were identified in 160 of 120 
1048 cases (15.3%). The frequency of BMPR2 mutations in familial PAH was 75.9%, in 121 
sporadic cases 12.2%, and 8.3% in anorexigen-exposed PAH cases. Forty-eight percent of 122 
BMPR2 mutations were reported previously17, and the remainder were newly identified in 123 
this study. Fourteen percent of BMPR2 mutations resulted in the deletion of larger protein-124 
coding regions ranging from 5 kb to 3.8 Mb in size. Supplementary Data 1 provides the 125 
breakdown of BMPR2 SNVs and indels, and the larger deletions are shown in Figure 2a-c 126 
with a detailed summary in Supplementary Table 2. 127 
 128 
Of the other genes previously reported in PAH we identified deleterious heterozygous rare 129 
variants in ACVRL1 (9 cases, 0.9%), ENG (6 cases, 0.6%), SMAD9 (4 cases, 0.4%), KCNK3 130 
(4 cases, 0.4%), and TBX4 (14 cases, 1.3%). We identified one case with highly deleterious 131 
variants in both BMPR2 (p.Cys123Arg) and SMAD9 (p.Arg294Ter). Details of consequence 132 
types, deleteriousness and conservation scores, and minor allele frequencies are provided in 133 
Supplementary Data 2. Fourteen cases (1.3%) with biallelic EIF2AK4 mutations were 134 
found19. No pathogenic coding variants in CAV1, SMAD1 or SMAD4 were identified. Taken 135 
together, rare causal variation in non-BMPR2 disease genes (TBX4, ENG, ACVRL1, 136 
SMAD9, KCNK3 and EIF2AK4) accounted for 4.7% of the entire PAH cohort. The clinical 137 
characteristics of cases with variants in these previously reported genes are shown in 138 
Supplementary Table 3. 139 
 140 
In a case-control comparison of the frequencies of deleterious variants confined to the 141 
previously reported PAH genes, we observed significant overrepresentation of rare variants 142 
in BMPR2, TBX4, ACVRL1 and biallelic variants in EIF2AK4 only (P < 0.05) (Supplementary 143 
Table 4). 144 
Identification of novel PAH disease genes 145 
The strategy to identify novel causative genes in PAH employed a series of case-control 146 
analyses (Figure 1b). To identify signals that might be masked by variants in previously 147 
reported PAH genes, we excluded subjects with rare variants and deletions in BMPR2, 148 
EIF2AK4, ENG, ACVRL1, TBX4, SMAD9 and KCNK3. A genome-wide comparison of 149 
protein truncating variants (PTVs), representative of high impact variants, identified a higher 150 
frequency of PTVs in ATP13A3 (6 cases) (Padj = 0.0346). Moreover, we identified additional 151 
PTVs in several putative PAH genes, including EVI5 (5 cases, 1 control) and KDR (4 cases, 152 
0 controls) (Figure 3a), that require further validation to evaluate their contribution to PAH 153 
pathogenesis (Supplementary Table 5). 154 
 155 
We next analysed rare missense variants overrepresented in the PAH cohort, again 156 
excluding subjects with variants in the previously reported PAH genes. This revealed 157 
significant overrepresentation of rare variants in GDF2 after correction for multiple testing 158 
(Padj = 0.0023), followed by AQP1 (Figure 3b and Supplementary Table 6). Next, in a 159 
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combined analysis of rare missense variants and PTV, only GDF2 remained significant (P = 160 
0.001). Rare variants in additional putative genes occurred at higher frequency in cases 161 
compared to controls, including AQP1, ALPPL2, ATP13A3, OR8U1, IFT74, FLNA, SOX17, 162 
ATP13A5, C3orf20 and PIWIL1 (uncorrected P value < 0.0005), but were not significant after 163 
correction for multiple testing (Figure 3c and Supplementary Table 7). 164 
 165 
In order to increase power to detect rare associations, we deployed SKAT-O on filtered rare 166 
PTVs and missense variants. Excluding previously reported genes, this analysis revealed an 167 
association with rare variants in AQP1 (Padj = 4.28x10
-6) and SOX17 (Padj = 6.7x10
-5) (Figure 168 
3d). AQP1 and SOX17 were both also nominally significant in the combined burden tests, 169 
described above. Association was also found with rare variants in MFRP (Padj = 1.3x10
-5). 170 
However, we consider MFRP a false-positive finding for reasons given in the Discussion. 171 
Supplementary Table 8 shows the top 50 most significant genes identified by SKAT-O, 172 
providing further candidates to be evaluated in future studies. Details of rare variants in 173 
novel PAH genes (GDF2, ATP13A3, AQP1, SOX17) identified in cases are provided in 174 
Supplementary Data 3. 175 
 176 
Notably, a genome-wide assessment of larger structural variation did not identify any 177 
additional large deletions after exclusion of subjects harbouring deletions in BMPR2 (Figure 178 
2d-e).  179 
 180 
The proportion of PAH cases with mutations in the new genes was 3.5%. The clinical 181 
characteristics of PAH cases with mutations in these genes are provided in Supplementary 182 
Table 3b. Of note, cases with mutations in SOX17 and AQP1 were significantly younger at 183 
diagnosis (32.8 ± 16.2 years [P = 0.002] and 36.9 ± 14.3 years [P = 0.013], respectively) 184 
compared to cases with no mutations in the previously established genes (51.7 ± 16.6 185 
years).  186 
Non-coding variation around PAH disease genes 187 
An initial analysis for enrichment of variants in the non-coding sequence surrounding 188 
previously reported and newly identified PAH disease genes, including upstream gene 189 
regions, 5’ UTRs, intronic sequence, 3’ UTRs and downstream gene regions, did not detect 190 
an significant overrepresentation in the PAH cohort. Details of the non-coding variants that 191 
passed the filtering strategy are provided in Supplementary Data 4. 192 
Independent validation and familial segregation analysis 193 
To provide further validation of the potentially causal role of mutations in the new genes 194 
identified, we examined whole-exome data from an independent UK family with three 195 
affected individuals across two generations. Microsatellite genotyping across chromosome 196 
2q33 had previously demonstrated non-sharing of haplotypes in affected individuals, 197 
consistent with exclusion of linkage to the BMPR2 locus. No pathogenic variants were 198 
identified in the protein-coding regions of the BMPR2 gene or other TGF-β pathway genes. 199 
Analysis of exome sequence data from individual II-1 identified a novel heterozygous 200 
c.411C>G (p.Y137*) PTV in the SOX17 gene. Segregation analysis in the extended family 201 
demonstrated that the mutation had arisen de novo in the affected father (II-1) and was 202 
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transmitted to the affected offspring (III-1). All unaffected family members were confirmed as 203 
wild-type (Figure 4a).  204 
 205 
Three HPAH subjects harbouring rare variants in AQP1, identified in the NIHR BR-RD WGS 206 
study, were also selected for familial co-segregation analysis (Figure 4b-d). No pathogenic 207 
variants in any of the previously reported genes were identified in these families. The first 208 
pedigree comprised three affected individuals across two generations. Sanger sequencing 209 
confirmed the presence of the heterozygous AQP1 c.583C>T (p.R195W) missense variant 210 
in the proband (E011942), the affected father (E011942.f) and the healthy younger paternal 211 
uncle (E011942.u1). An additional unaffected uncle did not carry the AQP1 variant. These 212 
results indicate likely incomplete penetrance in the unaffected carrier, as observed in 213 
BMPR2 families20. No additional clinical information was available for the deceased 214 
grandparents (Figure 4b). The remaining two families comprised affected parent-offspring 215 
individuals. By Sanger sequencing we independently confirmed a heterozygous AQP1 216 
c.527T>A (p.Val176Glu) missense variant in proband (E012415) and his affected father 217 
(Figure 4c), as well as a heterozygous AQP1 c.583C>T (p.R195W) missense variant in 218 
proband (E010634) and her affected father (Figure 4d). These results highlight recurrent 219 
AQP1 variation across unrelated families and demonstrate co-segregation with the 220 
phenotype.  221 
Predicted functional impact of variants in novel PAH genes 222 
To evaluate the potential functional impact of rare variants identified in the likely causative 223 
new genes we performed structural analysis of GDF2, ATP13A3, AQP1, and SOX17. In 224 
addition we undertook a functional analysis of the GDF2 variants identified.  225 
 226 
Heterozygous mutations in GDF2 exclusive to PAH cases comprised 1 frameshift variant 227 
and 7 missense variants. GDF2 encodes growth and differentiation factor 2, also known as 228 
bone morphogenetic protein 9 (BMP9), the major circulating ligand for the endothelial 229 
BMPR2/ACVRL1 receptor complex21. Amino acid substitutions were assessed against the 230 
published crystal structure22 of the prodomain bound form of GDF2 (Figure 5). Variants 231 
clustered at the interface between the prodomain and growth factor domain. Since the 232 
prodomain is important for the processing of GDF2, it is likely that amino acid substitutions 233 
reduce the stability of the prodomain-growth factor interface. In keeping with these 234 
predictions, HEK293T cells transfected with GDF2 variants exclusive to PAH cases, 235 
demonstrated reduced secretion of mature GDF2 into the cell supernatants (Figure 5d), 236 
compared with wild type GDF2. 237 
 238 
We identified 3 heterozygous frameshift variants, 2 stop gained, 2 splice region variants in 239 
ATP13A3, which are predicted to lead to loss of ATPase catalytic activity (Figure 6a). In 240 
addition, we identified 4 heterozygous likely pathogenic missense variants in PAH cases, 241 
two near the conserved ATPase catalytic site and predicted to destabilise the conformation 242 
of the catalytic domain (Figure 6b-d). The distribution of variants (Figure 6a) suggests that 243 
these mutations impact critically on the function of the protein.  244 
 245 
The majority of rare variants identified in AQP1, which encodes aquaporin 1, are situated 246 
within the critical water channel (Figure 7). In particular the p.Arg195Trp variant, identified in 247 
5 PAH cases, locates at the hydrophilic face of the pore. This arginine at position 195 helps 248 
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define the constriction region of the AQP1 pore structure and is conserved across the water 249 
specific aquaporins26. Rare variants in SOX17, included 4 nonsense variants (including the 250 
PTV identified in the additional UK family) predicted to lead to loss of the beta-catenin 251 
binding region, and 6 missense variants predicted to disrupt interactions with Oct4 and beta-252 
catenin27, 28 (Figure 8). 253 
 254 
GDF2 is known to be secreted from the liver, but the cellular localization of proteins encoded 255 
by the other novel genes is less well characterised. Thus we employed 256 
immunohistochemistry to examine localisation in the normal and hypertensive human 257 
pulmonary vasculature. Figure 9 shows that AQP1, ATP13A3 and SOX17 are predominantly 258 
localised to the pulmonary endothelium in normal human lung and to endothelial cells within 259 
plexiform lesions of patients with idiopathic PAH. In addition, we determined the relative 260 
mRNA expression levels of AQP1, ATP13A3 and SOX17 in primary cultures of pulmonary 261 
artery smooth muscle cells (PASMCs), pulmonary artery endothelial cells (PAECs) and 262 
blood outgrowth endothelial cells (BOECs)31. AQP1 was expressed in PASMCs and 263 
endothelial cells, with a trend towards higher levels in PASMCs (Figure 10a). ATP13A3 was 264 
highly expressed in both cell types (Figure 10b), whereas SOX17 was almost exclusively 265 
expressed in endothelial cells (Figure 10c). Although AQP1 and SOX17 are known to play 266 
roles in endothelial function, the function of ATP13A3 in vascular cells is entirely unknown. 267 
Thus, we determined the impact of ATP13A3 knockdown on proliferation and apoptosis of 268 
BOECs. Loss of ATP13A3 led to marked inhibition of serum-stimulated proliferation of 269 
BOECs, and increased apoptosis in serum-deprived conditions (Figure 10d-f). 270 
Discussion 271 
We report a comprehensive analysis of rare genetic variation in a large cohort of index cases 272 
with idiopathic and heritable forms of PAH. Whilst we utilised WGS, the main goal was the 273 
identification of rare causal variation underlying PAH in the protein coding sequence. The 274 
approach involved a rigorous case-control comparison using a tiered search for variants. 275 
First, we searched for high impact PTVs overrepresented in cases, having excluded 276 
previously established PAH genes. This revealed PTVs in ATP13A3, a poorly characterised 277 
P-type ATPase of the P5 subfamily32. There is little information regarding the function of the 278 
ATPase, ATP13A3, which appears widely expressed in mouse tissues32. Although, the 279 
precise substrate specificity is unknown, ATP13A3 plays a role in polyamine transport33. 280 
Based on available RNA sequencing data, ATP13A3 is highly expressed in human 281 
pulmonary vascular cells and cardiac tissue (https://www.encodeproject.org). We confirmed 282 
that ATP13A3 mRNA is expressed in primary cultured pulmonary artery smooth muscle cells 283 
and endothelial cells, and provide preliminary data that loss of ATP13A3 inhibits proliferation 284 
and increases apoptosis of endothelial cells. These findings are consistent with the widely 285 
accepted paradigm that endothelial apoptosis is a major trigger for the initiation of PAH34, 35. 286 
It will be of considerable interest to determine the role of ATP13A3 in vascular cells and 287 
whether it is functionally associated with BMP signalling, or represents a distinct therapeutic 288 
target in PAH. 289 
 290 
Analysis of missense variation, and a combined analysis of all predicted deleterious 291 
variation, revealed that mutation at the GDF2 gene is also significant determinant of 292 
predisposition to PAH. Of the new genes identified, GDF2 provides further evidence for the 293 
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central role of the BMP signalling pathway in PAH. GDF2 encodes the major circulating 294 
ligand for the endothelial BMPR2/ACVRL1 receptor complex21. Taken together, the genetic 295 
findings suggest that a deficiency in GDF2/BMPR2/ACVRL1 signalling in pulmonary artery 296 
endothelial cells is critical in PAH pathobiology. The majority of GDF2 variants detected in 297 
our adult-onset PAH cohort were heterozygous missense variants, in contrast to a previous 298 
case report of childhood onset PAH due to a homozygous nonsense mutation36. The finding 299 
of causal GDF2 variants in PAH cases, associated with reduced production of GDF2 from 300 
cells, provides further support for investigating replacement of this factor as a therapeutic 301 
strategy in PAH37. 302 
 303 
To maximise the assessment of rare variation in a case-control study design, we deployed 304 
the SKAT-O test. This approach revealed a significant association of rare variation in the 305 
aquaporin gene, AQP1, and the transcription factor encoded by SOX17. Of note, both AQP1 306 
and SOX17 were within the top 8 ranked genes in our combined PTV and missense burden 307 
test analysis (Supplementary Table 7), providing further confidence in their causative 308 
contribution to PAH.  309 
 310 
Aquaporin 1 belongs to a family of membrane channel proteins that facilitate water transport 311 
in response to osmotic gradients26, and AQP1 is known to promote endothelial cell migration 312 
and angiogenesis38. Thus, approaches that maintain or restore pulmonary endothelial 313 
function could offer new therapeutic directions in PAH. Conversely, AQP1 inhibition in 314 
pulmonary artery smooth muscle cells ameliorated hypoxia-induced pulmonary hypertension 315 
in mice39, suggesting that further studies are required to determine the key cell type 316 
impacted by AQP1 mutations in human PAH, and the functional impact of these AQP1 317 
variants on water transport. The demonstration of familial segregation of AQP1 variants with 318 
PAH provides further support for the potentially causal role of these mutations in disease. 319 
However, we also identified an unaffected AQP1 variant carrier consistent with reduced 320 
penetrance, which is well described for other PAH genes, including BMPR2.  321 
 322 
Although functional studies are required to confirm the mechanisms by which mutations in 323 
SOX17 cause PAH, this finding provides additional support for the vascular endothelium as 324 
the major initiating cell type in this disorder. SOX17 encodes the SRY-box containing 325 
transcription factor 17, which plays a fundamental role in angiogenesis40 and arteriovenous 326 
differentiation41. Moreover, conditional deletion of SOX17 in mesenchymal progenitors leads 327 
to impaired formation of lung microvessels42. The demonstration of familial segregation of 328 
the SOX17 p.Y137* PTV with early onset PAH provides additional evidence for a causal role 329 
for these variants in PAH. The co-existence of a patent ductus arteriosus in the index case 330 
and an atrial septal defect (ASD) in one of the affected offspring is of interest and suggests 331 
an association with congenital heart disease. Small ASDs are not uncommon in idiopathic 332 
PAH, and a more detailed clinical phenotyping of SOX17 mutation carriers will be required to 333 
determine whether the presence of ASDs and other congenital heart abnormalities are more 334 
common in carriers of these mutations. 335 
 336 
Whilst the SKAT-O analysis also provided support for the MFRP gene, recessive bi-allelic 337 
mutations in MFRP cause retinal degeneration and posterior microphthalmos43. The 338 
expression of MFRP transcripts is largely confined to the central nervous system44 and the 339 
majority of variants were present in the Genome Aggregation Database (GnomAD, 340 
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http://gnomad.broadinstitute.org). On the basis of these considerations, variants in MFRP 341 
are unlikely to contribute to PAH aetiology. 342 
 343 
This analysis provides new insights on the frequency and validity of previously reported 344 
genes in PAH. We confirmed that mutations in BMPR2 are the most common genetic cause 345 
and validated rare causal variants in ACVRL1, ENG, SMAD9, TBX4, KCNK3 and EIF2AK4. 346 
Although our findings question the validity of CAV1, SMAD1 and SMAD4 as causal genes, 347 
previous reports might represent private mutations occurring in very rare families. The use of 348 
WGS in this study allowed closer interrogation of larger deletions around the BMPR2 locus 349 
than has been possible previously. Nevertheless, additional analyses are required to 350 
determine the full impact of structural variation (inversions, duplications, smaller deletions) at 351 
this and other loci. 352 
 353 
The non-PAH cohort used in the case-control comparisons for this study comprised 354 
individuals, or relatives of individuals, with other rare diseases recruited to the NIHR 355 
Bioresource for Rare Diseases (NIHR BR-RD) in the UK (see Methods). In general, for very 356 
rare causal variants, the comparison between PAH cases and non-PAH rare disease 357 
controls should not reduce our ability to detect overrepresentation of rare variants in a 358 
particular gene in the PAH cohort, if mutations in that gene are specific to PAH. However, if 359 
rare variants in a gene were responsible for more than one phenotype, it is possible that this 360 
would reduce the power to detect overrepresentation in the PAH cohort. For example, if 361 
mutations occurred in different functional domains of the expressed protein, this might lead 362 
to PAH if mutations affected one domain, but other phenotypes if they affected another 363 
domain. Overcoming this potential limitation will require additional analysis of the functional 364 
impact of variants and their distribution within a gene, and more detailed information on the 365 
phenotypes of subjects in the non-PAH group. 366 
 367 
Taken together, this study identifies rare sequence variation in new genes underlying 368 
heritable forms of PAH, and provides a unique resource for future large-scale discovery 369 
efforts in this disorder. Mutations in previously established genes accounted for 19.9% of 370 
PAH cases. Including new genes identified in this study (GDF2, ATP13A3, AQP1, SOX17), 371 
the total proportion of cases explained by mutations increased to 23.5%. It is likely that 372 
independent confirmation of the expanded list of putative genes identified in this study will 373 
increase further the proportion of cases explained by mutations, but this will require larger 374 
international collaborations. The results suggest that the genetic architecture of PAH, 375 
beyond mutations in BMPR2, is characterised by substantial genetic heterogeneity and 376 
consists of rare heterozygous coding region mutations shared by small numbers of cases. 377 
The contribution of rare variation within non-coding regulatory regions to PAH aetiology 378 
remains to be determined. This will require functional annotation of regulatory and other non-379 
coding regions specific for relevant cell types, further case-control analyses of these regions 380 
and ultimately functional studies of gene regulation to assess the pathogenicity of non-381 
coding variants. Our findings to date provide support for a central role of the pulmonary 382 
vascular endothelium in disease pathogenesis, and suggest new mechanisms that could be 383 





Ethics and patient selection 387 
Cases were recruited from the UK National Pulmonary Hypertension Centres, Universite 388 
Sud Paris (France), the VU University Medical Center Amsterdam (The Netherlands), the 389 
Universities of Gießen and Marburg (Germany), San Matteo Hospital, Pavia (Italy), and 390 
Medical University of Graz (Austria). All cases had a clinical diagnosis of idiopathic PAH, 391 
heritable PAH, drug- and toxin-associated PAH, or PVOD/PCH established by their expert 392 
centre. The non-PAH cohort for the case-control comparison comprised 6385 unrelated 393 
subjects recruited to the NIHR BR-RD study. All PAH and non-PAH patients provided written 394 
informed consent (UK Research Ethics Committee: 13/EE/0325), or local forms consenting 395 
to genetic testing in deceased patients and non-UK cases. An additional UK family 396 
diagnosed with HPAH was ascertained as described previously45. Blood and saliva samples 397 
were collected under written informed consent of the participants or their parents for use in 398 
gene identification studies (UK Research Ethics Committee: 08/H0802/32).  399 
Composition of non-PAH control cohort 400 
The non-PAH control cohort consisted of subjects with bleeding, thrombotic and platelet 401 
disorders (15.5%), cerebral small vessel disease (2.1%), Ehlers-Danlos syndrome (0.3%), 402 
subjects recruited to Genomics England Ltd (19.8%), hypertrophic cardiomyopathy (3.6%), 403 
intrahepatic cholestasis of pregnancy (4.1%), Leber hereditary optic neuropathy (0.9%), 404 
multiple primary tumours (7.8%), neuropathic pain disorder (2.6%), primary immune 405 
disorders (15.3%), primary membranoproliferative glomerulonephritis (2.3%), retinal 406 
dystrophies/paediatric neurology and metabolic disease (19.8%), stem cell and myeloid 407 
disorders (2.1%), steroid resistant nephrotic syndrome (3.6%), and others (0.3%), or their 408 
first degree relatives. 409 
High-throughput sequencing 410 
DNA extracted from venous blood underwent whole genome sequencing using the Illumina 411 
TruSeq DNA PCR-Free Sample Preparation kit (Illumina Inc., San Diego, CA, USA) and 412 
Illumina HiSeq 2000 or HiSeq X sequencer, generating 100 - 150 bp reads with a minimum 413 
coverage of 15X for ~95% of the genome (mean coverage of 35X). Whole-exome 414 
sequencing was conducted for individual II-1 (Figure 4a) using genomic DNA extracted from 415 
peripheral blood. Paired-end sequence reads were generated on an Illumina HiSeq 2000. 416 
Generation of analysis-ready data sets 417 
Sequencing reads were pre-processed by Illumina with Isaac Aligner and Variant Caller (v2, 418 
Illumina Inc.) using human genome assembly GRCh37 as reference. Variants were 419 
normalised, merged into multi-sample VCF files by chromosome using the gVCF 420 
aggregation tool agg (https://github.com/Illumina/agg) and annotated with Ensembl’s Variant 421 
Effect Predictor (VEP). Following read alignment to the reference genome (GRCh37), variant 422 
calling and annotation of whole-exome data for individual II:1 were performed using GATK 423 
UnifiedGenotyper46 and ANNOVAR47, respectively. Annotations included minor allele 424 
frequencies from other control data sets (i.e. ExAC48, 1000 Genomes Project49 and UK10K50) 425 
as well as deleteriousness and conservation scores (i.e. CADD51, SIFT52, PolyPhen-253 and 426 
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Gerp54) enabling further filtering and assessment of the likely pathogenicity of variants. To 427 
take forward only high quality calls, the pass frequency (proportion of samples containing 428 
alternate alleles that passed the original variant filtering) and call rate (proportion of samples 429 
with reference or alternate genotypes) were combined into the overall pass rate (OPR: pass 430 
frequency x call rate) and variants with an OPR of 80% or higher were retained. 431 
Estimation of ethnicity and relatedness 432 
We estimated the population structure and relatedness based on a representative set of 433 
SNPs using the R package GENESIS to perform PC-Air55 and PC-Relate56, respectively. 434 
The selected 35,114 autosomal SNPs were present on Illumina genotyping arrays 435 
(HumanCoreExome-12v1.1, HumanCoreExome-24v1.0, HumanOmni2.5-8v1.1), do not 436 
overlap quality control excluded regions or multiallelic sites in the 1000 Genomes (1000G) 437 
Phase 3 dataset49, do not have any missing genotypes in NIHR BR-RD, had a MAF of 0.3 or 438 
above and LD pruning was performed using PLINK57 with a window size of 50 bp, window 439 
shift of 5 bp and a variance inflation factor threshold of 2. The 2,110 samples from the 440 
1000G Project including the European (EUR), African (AFR), South Asian (SAS) and East 441 
Asian (EAS) populations (excluding the admixed American population) were filtered for the 442 
selected SNPs and the filtered data were used to perform a principal component analysis 443 
(PCA) using PC-Air. We modelled the scores of the leading five principal components as 444 
data generated by a population specific multivariate Gaussian distribution and estimated the 445 
corresponding mean and covariance parameters. Genotypes from the NIHR BR-RD samples 446 
were projected onto the loadings for the leading five principal components from the 1000G 447 
PCA and we computed the likelihood that each sample belonged to each subpopulation 448 
under a mixture of multivariate Gaussians models. Each sample was allocated to the 449 
population with the highest likelihood, unless the highest likelihood was similar to likelihood 450 
values for other populations, as might be expected for example under admixed ancestry or if 451 
the sample came from a population not included in 1000G. Such ambiguous samples were 452 
labeled as “other”. PC-Relate was used to to identify related individuals in NIHR BR-RD. We 453 
used the first 20 PCs from PC-Air to adjust for relatedness and extracted the pairwise 454 
Identity-By-State distances and kinship values. The pairwise information was used by 455 
Primus to infer family networks and calculate the maximum set of unrelated samples.  456 
 457 
Of the 9,110 NIHR BR-RD samples, we assigned 80.2% to Non-Finish European (n=7,307), 458 
7.2% to South Asian (n=649), 2.3% to African (n=213), 0.08% to East Asian (n=78), 0.02% 459 
to Finnish-European (n=19) and 9.2% to Other (n=844) and retrieved a maximum set of 460 
7,493 unrelated individuals (UWGS10K), representing 82.2% of the entire NIHR BR-RD 461 
cohort. 462 
Cohort definition and allele frequency calculation 463 
Based on the relatedness analysis, we defined the following sample subsets: (a) the 464 
maximum number of unrelated non-PAH controls (UPAHC, n=6385), (b) all affected PAH 465 
cases (PAHAFF, n=1048), and (c) all unrelated PAH index cases (PAHIDX, n=1038). These 466 
subsets were used to annotate the variants in the multi-sample VCF file with calculated 467 
minor allele frequencies using the fill-tags extension of BCFtools58. 468 
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Rare variant filtering 469 
Filtering of rare variants was performed as follows: 1) variants with a MAF less than 1 in 470 
10,000 in UPAHC subjects, UK10K and ExAC were retained (adjusted for X chromosome 471 
variants to 1 in 8,000); 2) variants with a combined annotation dependent depletion 472 
deleteriousness (CADD) score of less than 15 were excluded. CADD scores were calculated 473 
using the CADD web service (http://cadd.gs.washington.edu) for variants lacking a score; 3) 474 
premature truncating variants (PTVs) or missense variants of the canonical transcript were 475 
retained; 4) missense variants predicted to be both tolerated and benign by SIFT and 476 
PolyPhen-2, respectively, were removed. 477 
 478 
To identify likely causative mutations (as reported in Supplementary Table 3), variants in 479 
previously reported and putative genes, identified in this study, were examined in more detail 480 
to exclude variants that did not segregate in families (where data available). Furthermore, 481 
variants shared between cases and non-PAH controls, as well as variants of uncertain 482 
significance that co-occurred with previously reported causative mutations or high impact 483 
PTVs were also excluded. 484 
Burden analysis of protein-truncating and missense variants 485 
Filtered variants were grouped per gene and consequence type (predicted PTV / missense) 486 
and subjects with at least one variant were counted (no double counting) per group and 487 
tested for association with disease. We applied a one-tailed Fisher’s exact test with post hoc 488 
Bonferroni correction to calculate the P value for genome-wide significance. 489 
Rare variant analysis using SKAT-O 490 
To further investigate the aggregated effect that rare variants contribute to PAH aetiology, 491 
we applied a Sequence Kernel Association test (SKAT-O). SKAT-O increases the power of 492 
discovery under different inheritance models by combining variance-component and burden 493 
tests. Variants were filtered based on MAF as specified above, and only PTV and missense 494 
variants were included. For the analysis we implemented SKAT-O in RvTests v1.9.959 with 495 
default parameters and weights being Beta(1,25), and applying a correction for read length, 496 
gender and the first five principal components of the ethnicity PCA. Variants were collapsed 497 
considering only the protein-coding region in the canonical transcript of the protein-coding 498 
genes in the genome assembly GRCh37. 499 
Analysis of large deletions 500 
Copy number variation was identified using Canvas60 and Manta61. Deletions called by both 501 
Manta and Canvas with a reciprocal overlap of ≥ 20% were retained. Of these, deletions 502 
were excluded if both failed standard Illumina quality metrics or overlapped with known 503 
benign deletions in healthy cohorts62. Deletions with a reciprocal overlap of ≥ 50% between 504 
samples were merged and filtered for a frequency of less than 1 in 1,000 in WGS10K and 505 
overlapping exonic regions of protein coding genes (GRCh37 genome assembly). The 506 
number of subjects with deletions were added up by gene (no double counting of subjects) 507 
and tested for association with the disease. We applied a one-tailed (greater) Fisher’s exact 508 
test with Bonferroni post hoc correction for multiple testing to determine the P values for 509 
genome-wide significance. 510 
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Confirmation of variants 511 
Variant sequencing reads for SNVs, indels and deletions were visualised for validation on 512 
Integrative Genomes Viewer (IGV)18, and were confirmed by diagnostic capture-based high-513 
throughput sequencing, if the IGV inspection was not satisfactory. For the familial 514 
segregation analysis, linkage to the BMPR2 locus was first examined by microsatellite 515 
genotyping analysis. Mutation screening of the BMPR2, ACVRL1, ENG, AQP1 and SOX17 516 
genes was conducted by capillary sequencing using BigDye Terminator v3.1 chemistry. All 517 
DNA fragments were resolved on an ABI Fragment Analyzer (Applied Biosystems). All 518 
primer sequences are listed in Supplementary Table 9. The family trees were drawn using 519 
the R package FamAgg63.  520 
Structural analysis of novel variants 521 
The domain structures and the functional groups of the novel PAH genes were plotted 522 
according to the entry in UniProtKB. Clustal Omega was used for sequence alignment. 523 
Structural data were obtained from RCSB Protein Data Bank and analysed according to 524 
published reports. Figures were generated using PyMOL Molecular Graphics System. 525 
Production of pGDF2 Wild Type and Variant Proteins 526 
The cloning of human wild type pro-GDF2 (pGDF2) in pCEP4 has been described 527 
previously64. Site-directed mutagenesis was performed according to the manufacturer’s 528 
instructions (QuickChange Site Directed Mutagenesis Kit, Agilent Technologies). Mutations 529 
were confirmed by Sanger sequencing. HEK-EBNA cells were transfected with plasmids 530 
containing either wild-type or mutant pGDF2 for 14 hours. The transfecting supernatant was 531 
removed and replaced with CDCHO media (Invitrogen) for 5 days to express the proteins. 532 
The conditioned media containing GDF2 and the variants were harvested and snap-frozen 533 
on dry-ice before being stored at -80oC. For each variant, conditioned media from three 534 
independent transfections were collected for further characterisation.  535 
GDF2 ELISA 536 
High binding 96-well ELISA plates (Greiner, South Lanarkshire, UK) were coated with 537 
0.2µg/well of mouse monoclonal anti-human GDF2 antibody (R&D Systems, Oxfordshire, 538 
UK) in PBS (0.1M phosphate pH7.4, 0.137M NaCl, 2.7mM KCl, Sigma) overnight at 4oC in a 539 
humidified chamber. Plates were washed with PBS containing 0.05% (v/v) Tween-20 (PBS-540 
T), followed by blocking with 1% bovine serum albumin in PBS-T (1% BSA/PBS-T) for 90min 541 
at room temperature. Recombinant human GDF2 standards (1-3000pg/ml) or conditioned 542 
media samples (100µl/well of 1:30, 1:100, 1:300, 1:1000, 1:3000 and 1:10000 dilutions) 543 
were then added and incubated for 2h at room temperature. After washing, plates were then 544 
incubated with 0.04µg/well biotinylated goat anti-human GDF2 (R&D Systems) in 1% 545 
BSA/PBS-T for 2hr. Plates were washed, then incubated with ExtrAvidin(r)-Alkaline 546 
phosphatase (Sigma) diluted 1:400 in 1% BSA/PBS-T for 90 min. Plates were washed with 547 
PBS-T followed by water. The ELISA was developed with a colorimetric substrate 548 
comprising 1mg/ml 4-Nitrophenyl phosphate disodium salt hexahydrate (Sigma) in 1M 549 
Diethanolamine, pH9.8 containing 0.5mM MgCl2. The assay was developed in the dark at 550 
room temperature and the absorbance measured at 405nm. 551 
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Cell culture and treatments 552 
Distal human pulmonary artery smooth muscle cells (PASMCs) were cultured from explants 553 
dissected from lung resection specimens. Small pulmonary arterioles (0.5 to 2mm diameter) 554 
were dissected and divided into small pieces before plating in T25 flasks. Explants were left 555 
to adhere for 2 hours and then incubated in DMEM/20% FBS plus amino acids at 37oC in 556 
95% air/5% CO2 until PASMCs had formed confluent monolayers. Cells were then 557 
trypsinized, and for subsequent passages cells were maintained in DMEM supplemented 558 
with 10% FBS. The cellular phenotype of PASMCs was confirmed by positive 559 
immunofluorescence staining with anti-smooth muscle specific alpha-actin (Clone IA4 560 
Sigma-Aldrich; 1:100 dilution). The derivation of human tissues and cells was approved by 561 
Papworth Hospital ethical review committee (Ref 08/H0304/56+5) and all subjects provided 562 
informed and written consent. 563 
 564 
Human blood outgrowth endothelial cells (BOECs) were derived from 40–80 ml of peripheral 565 
venous blood isolated from healthy subjects. The study was approved by the 566 
Cambridgeshire 3 Research Ethics Committee (Ref 11/EE/0297), and all subjects provided 567 
informed and written consent. BOECs were cultured in 10% FBS supplemented with EGM-568 
2MV (Life Technologies, Carlsbad, CA). Cells were used between passages 4 and 865. The 569 
endothelial phenotype of BOECs was determined by flow cytometry for expression of 570 
endothelial surface markers, as described previously31. Cells were routinely tested to 571 
exclude mycoplasma infection.  572 
 573 
Human pulmonary artery endothelial cells (PAECs) were purchased from Lonza (Cat. No. 574 
CC-2530; Basel, Switzerland). Cells were maintained in EGM-2 with 2% FBS (Lonza). 575 
PAECs were used for experiments between passages 4 and 8. For experiments cells were 576 
cultured in the presence of EBM-2 containing Antibiotic-Antimycotic (Invitrogen, 577 
Renfrewshire, UK). Cells were routinely tested to exclude mycoplasma contamination. 578 
RNA preparation and quantitative reverse transcription-PCR 579 
Total RNA was extracted using RNeasy Mini Kit with DNAse digestion (Qiagen, West 580 
Sussex, UK), according to the manufacturer’s instructions. cDNA was prepared from 1 µg of 581 
RNA using High Capacity Reverse Transcriptase kit (Applied Biosystems, Foster City, CA). 582 
Quantitative PCR reactions employed MicroAmp optical 96-well reaction plates (Applied 583 
Biosystems).  50 ng µl-1 cDNA was used with SYBR Green Jumpstart Taq Readymix 584 
(Sigma-Aldrich), ROX reference dye (Invitrogen) using custom made sense and anti-sense 585 
primers (all 200 nmol l-1). Primers for human ACTB (encoding β-actin), AQP1, ATP13A3, 586 
B2M, HPRT and SOX17 were designed using PrimerBLAST 587 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/) (Supplementary Table 9). Reactions were 588 
amplified on a Quantstudio 6 Real-Time PCR system (Applied Biosystems). The relative 589 
abundance of each target gene in different cell lines was compared using the equation 2-590 
(CtGOI-Ct3HK), where Ct3HK corresponded to the arithmetic mean of the Cts for ACTB, B2M and 591 
HPRT for each sample. For expression analysis of siRNA knockdown, the 2-(∆∆Ct) method 592 
was used and fold expression determined relative to the DH1 control. 593 
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siRNA transfection 594 
Prior to transfection, cells were preincubated in Opti-MEM-I reduced serum media 595 
(Invitrogen) for 2h before transfection with 10nM siRNA that had been lipoplexed for 20 min 596 
at RT with DharmaFECT1 (GE Dharmacon, Lafayette, CO). Cells were then incubated with 597 
the siRNA/DharmaFECT1 complexes for 4h at 37oC before replaced by full growth media. 598 
Cells were kept in growth media for 24h before further treatment. Knockdown efficiency was 599 
confirmed by mRNA expression or immunoblotting. For proliferation assays, parallel RNA 600 
samples were collected both on day0 and day6, confirming that ATP13A3 expression was 601 
reduced by >90% on Day 0 and still reduced by >70% at Day 6. For all other assays, parallel 602 
RNA samples were collected on the day of the experiment to confirm knockdown, which was 603 
>90%. The siRNAs used were oligos targeting ATP13A3 (SASI_Hs02_00356805) from 604 
Sigma-Aldrich and ON-TARGET plus non-targeting Pool (siCP; GE Dharmacon). 605 
Flow cytometric apoptosis assay 606 
BOECs were plated 150,000/well into 6-well plates and transfected with siATP13A3 or siCP 607 
lipoplexed with DharmaFECT1. Cells were then serum-starved in EBM-2 (Lonza) containing 608 
0.1% FBS and A/A for 8 hours before treating with EBM-2 and A/A containing either 609 
0.1%FBS or 5%FBS for another 24 hours. Cells were then trypsinized and after washing 610 
with PBS, stained using the FITC Annexin V Apoptosis Dectection Kit I (BD Biosciences). 611 
For each condition, dual-staining of 5µl FITC conjugated Annexin V and 5µl propidium iodide 612 
(PI) were added and incubated at room temperature for 15 minutes. For the single staining 613 
controls for compensation, either 5µl FITC Annexin V or 5µl PI was added into non-614 
transfected cells. All samples were analysed on BD Accuri™ C6 Plus platform (BD 615 
Biosciences). Data were collected and analysed using FlowJo software, with AnnexinV+/PI- 616 
cells defined as early apoptotic (Treestar). 617 
 618 
Caspase-Glo 3/7 assay 619 
BOECs were seeded at a density of 150,000/well into 6-well plates and transfected with 620 
siATP13A3 or siCP lipoplexed with DharmaFECT1. For each condition, cells were 621 
trypsinized from 6-well plates and reseeded in triplicates into a 96-well plate at a density of 622 
15,000-20,000/well and left to adhere overnight. Cells were quiesced in EBM-2 containing 623 
0.1%FBS for 24h before treating with or without EBM-2 and A/A containing either 0.1%FBS 624 
or 5%FBS for 16 hours. For measuring caspase activities, 100ul Caspase-Glo® 3/7 Reagent 625 
(G8091 Promega) was added into each well, incubated and mixed on a plate shaker in the 626 
dark for 30 minutes at room temperature. The lysates were transferred to a white-walled 96-627 
well plate and luminescence was read in a GloMax® luminometer (Promega). 628 
Data availability 629 
WGS data of PAH cases included in this manuscript and eligible for public release according 630 
to the UK Research Ethics rules have been deposited in the European Genome-phenome 631 
Archive (EGA) at the EMBL - European Bioinformatics Institute under accession number 632 
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Figure legends 855 
Figure 1 Flow diagrams illustrating (a) the composition of the NIHR BioResource – Rare 856 
Diseases PAH study and (b) the analysis strategy to identify novel PAH disease genes. (a) 857 
The study comprised 1048 adult cases (aged 16 or over) attending specialist pulmonary 858 
hypertension centres from the UK (n=731), and additional cases from France (n=142), The 859 
Netherlands (n=45), Germany (n=82) and Italy (n=48). (b) A series of case-control 860 
comparisons including and excluding cases with variants in previously reported disease 861 
genes were undertaken using complementary filtering strategies. 862 
 863 
Figure 2 Analysis of copy number deletions. (a) Deletions affecting the BMPR2 locus in 23 864 
PAH cases. Genes are indicated in orange and labelled with their respective gene symbol. 865 
Deletions are drawn as blue boxes above the genome axis (grey) showing the genomic 866 
position on chromosome 2. The grey box highlights the location of BMPR2. (b) Locus zoom 867 
on BMPR2 highlighting the focal deletions affecting one or more exons. (c) WGS coverage 868 
profiles of a selected set of smaller and larger deletions, visualised with the Integrative 869 
Genomics Viewer (IGV)18, with deletions highlighted by red bars. (d) and (e) Manhattan plots 870 
of the genome-wide case-control comparison of large deletions. In (d) all subject are 871 
considered. In (e) subject with larger deletions affecting the BMPR2 locus are excluded. The 872 
adjusted P value threshold of 5 x 10
-8 for genome-wide significance is indicated by the red 873 
line. 874 
 875 
Figure 3 Manhattan plots of the rare variant analyses, having excluded cases carrying rare 876 
variants in previously established PAH genes. Filtered variants were grouped per gene. We 877 
tested for an excess of variants in PAH cases within genes using Fisher’s exact test. The 878 
negative decadic logarithm of unadjusted or adjusted P-values are plotted against the 879 
chromosomal location of each gene. (a) Burden test of rare PTVs. (b) Burden test of rare 880 
deleterious missense variants. (c) Burden test combining rare PTVs and likely deleterious 881 
missense variants. (d) SKAT-O test of rare PTVs and missense variants. 882 
 883 
Figure 4 Pedigree structures and analysis of familial transmission of variants in AQP1 and 884 
SOX17. (a) Individual II.1 harbours a heterozygous de novo SOX17 c.411C>G (p.Y137*) 885 
PTV resulting in a premature termination codon, which has been transmitted to the affected 886 
male (III.1). No unaffected family members carry the variant. No sample was available from 887 
subject III.2. (b) Proband E011942 has inherited a heterozygous AQP1 c.583C>T 888 
(p.R195W) missense variant from her affected father. No sample was available from the 889 
affected sister of the proband. The younger healthy uncle of the index case also carries the 890 
AQP1 variant. No samples or further clinical information was available for the grandparents, 891 
who were not known to have cardiopulmonary disease. (c) Both the proband E012415 and 892 
her father are affected and carry the rare AQP1 c.527T>A (p.V176E) missense variant. 893 
There was no further information available about the siblings of the father. (d) Subject 894 
E010634 has inherited the heterozygous AQP1 c.583C>T (p.R195W) missense variant from 895 
her affected father. No rare variants in previously reported PAH genes were identified in any 896 
of theses families. Index cases are highlighted in red. yo: years old, mo: months old, d.: 897 
death. 898 
 899 
Figure 5 Structural analysis of GDF2 mutations. (a) Schematic diagram of GDF2 900 
processing. The pre-pro-protein is processed into the mature growth factor domain (GFD) 901 
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bound to the prodomain upon secretion23. (b) Plot of GDF2 mutations found only in PAH 902 
cases superimposed on the structure of prodomain bound GDF2 (PDB: 4YCG 903 
[http://dx.doi.org/10.2210/pdb4YCG/pdb])22. The GDF2 growth factor domain is shown in 904 
green and the prodomain in cyan. (c) Magnified view of the Arg110 and Glu143 mutations. 905 
The wild type amino acids make double salt bridges to stabilise the prodomain conformation 906 
at the interface between the growth factor domain and prodomain. The E143K and R110W 907 
mutations both disrupt these interactions, destabilising the interaction between the growth 908 
factor domain and prodomain. (d) GDF2 levels secreted into supernatants of HEK293T cells 909 
transfected with likely pathogenic variants found in PAH cases, compared with wild type 910 
GDF2 and cells transfected with an empty vector. *** P < 0.001 by ANOVA. 911 
 912 
Figure 6 Structural analysis of ATP13A3 mutations. (a) Topology of ATP13A3, plotted 913 
according to UniProtKB Q9H7F0 [http://www.uniprot.org/uniprot/Q9H7F0]. Frameshift and 914 
stop-gained mutations identified in PAH cases are shown as khaki circles, and missense 915 
mutations as red circles. Frameshift/stop-gained mutations are predicted to truncate the 916 
protein prior to the catalytic domain and essential Mg binding sites, leading to loss of 917 
ATPase activity. (b) Sequence alignment of ATP13A3 with ATP1A1 (P05024 918 
[http://www.uniprot.org/uniprot/P05024]), of which the high resolution structure was used for 919 
the structural analysis in (c). The conserved regions of ATP13A3 and ATP1A1, essential for 920 
ATPase activity24, show good alignment (data not shown). Only regions containing the 921 
missense PAH mutations are shown, with positions of the four missense mutations 922 
highlighted in yellow above the sequences. (c) Structural analysis of the 4 PAH missense 923 
mutations plotted on the ATP1A1 crystal structure based on the sequence alignment in (b) 924 
(PDB: 3wgu [http://dx.doi.org/10.2210/pdb3WGU/pdb])25. Green: α subunit (P05024 925 
[http://www.uniprot.org/uniprot/P05024]), cyan: β subunit (P05027 926 
[http://www.uniprot.org/uniprot/P05027]), grey: γ-subunit transcript variant a (Q58k79 927 
[http://www.uniprot.org/uniprot/Q58k79]). Y535, Y677, R685 and I787 are the numbering in 928 
ATP1A1. Positions of the four missense mutations found in PAH are labelled and highlighted 929 
by red circles. (d) Magnified view of the cytoplasmic region of the ATPase, showing the 930 
presence of ADP at the active site. The conserved regions essential for ATPase activity are 931 
shown in light pink. The L675V and R858H mutations are located close to the ATP catalytic 932 
region. 933 
 934 
Figure 7 Structural analysis of AQP1 mutations. (a) Multiple sequence alignment of human 935 
AQP1 with seven other mammals. The bovine AQP1 has the high resolution (2.2Å) 936 
published structure. Mutations identified in PAH cases are highly conserved and highlighted 937 
in yellow. (b) Crystal structure of bovine AQP1 (PDB: 1j4n 938 
[http://dx.doi.org/10.2210/pdb1J4N/pdb])26. Left: side view; right: top view from the 939 
extracellular direction. AQP1 is shown as a semi-transparent cartoon and five water 940 
molecules in the water channel are shown as red spheres. Key residues lining the water 941 
channels are represented with stick structures. (c) Magnified view of the water channel, with 942 
H-bonds connected to water molecules in the channel highlighted. Two asparagine-proline-943 
alanine (NPA) motifs, essential for the water transporting function of AQP1, are shown in 944 
magenta. Conserved His180 that constricts the water channel is shown in yellow. Mutations 945 
found in PAH cases, Arg195Trp and Val176Glu, are labelled and shown as orange stick 946 
structures. Arg195 and His180 are highly conserved in the known water channels and are 947 
strong indicators of water channel specificity. Arg195Trp and Val176Glu mutations are 948 




Figure 8 Structural analysis of SOX17 mutations. (a) Schematic diagram of human SOX17 951 
(Q9H6I2 [http://www.uniprot.org/uniprot/Q9H6I2]), based on UniProtKB annotation, and 952 
published reports27. Red arrows indicate PTVs and black arrows indicate missense 953 
mutations identified in PAH patients. The blue bar illustrates the region that is covered in the 954 
crystal structure (PDB: 3F27 [http://dx.doi.org/10.2210/pdb3F27/pdb])29. The ability of 955 
SOX17 to activate transcription of target genes correlates with binding to β-catenin27. As 956 
illustrated, all PTVs lead to a loss of the β-catenin binding region. Two missense mutations 957 
are located within and very close to the minimum β-catenin binding regions, and both are 958 
highly conserved, indicating they are likely to be important for β-catenin binding. (b) 959 
Structural analysis of HMG domain missense mutations found in PAH patients. Left, 960 
Superposition of SOX17/DNA structure (Sox17: cyan, DNA: grey)29 onto SOX2/DNA/Oct1 961 
structure (PDB: 1GT0 [http://dx.doi.org/10.2210/pdb1GT0/pdb], Sox2: yellow, Oct1: 962 
magenta, DNA: light blue)28. Right: Magnified view of the interactions around Arg140 in the 963 
SOX2/DNA/Oct structure. Arg140 in SOX2 makes multiple H-bond interactions and mutating 964 
this Arg in SOX2 abolishes the interaction with transcription factors Pax6 and Oct428. SOX2 965 
and SOX17 both bind to Oct430 and SOX17 K122E mutant can replace SOX2 in maintaining 966 
stem cell pluripotency30, indicating this region in SOX17 may interact with Oct4, similar to 967 
SOX2. The three missense mutations in SOX17 will likely disrupt interaction with Oct4. (c) 968 
Supporting the analysis in (b), sequence alignment shows that the HMG domain of SOX2 969 
(P48431 [http://www.uniprot.org/uniprot/P48431]) and SOX17 as well as SOX8 (P57073 970 
[http://www.uniprot.org/uniprot/P57073]) and SOX18 (P35713 971 
[http://www.uniprot.org/uniprot/P35713]) share high sequence identity and the three 972 
mutations found in PAH (highlighted in yellow) are highly conserved emphasising their 973 
functional importance. Similarly, the Gly and Thr that interact with Arg140 in SOX2 974 
(highlighted in yellow) are also conserved between Oct1 (PO2F1) and Oct4 (PO5F1). 975 
 976 
Figure 9 Immunolocalisation of AQP1, ATP13A3 and SOX17 in normal and PAH lung. The 977 
typical histological findings (haematoxylin and eosin staining) of concentric vascular lesions 978 
with associated plexiform lesions are shown (a). Higher magnification images of plexiform 979 
lesion (b), with frequent endothelialised channels (c; anti-CD31) surrounded by 980 
myofibroblasts (d; anti-SMα). Additional high magnification images demonstrating 981 
endothelial expression of ATP13A3 (e), AQP1 (f) and SOX17 (g) in PAH lung. Controls lung 982 
sections demonstrating predominantly endothelial expression of ATP13A3 (h), AQP1 (i) and 983 
SOX17 (j). (Scale bars = 50µm). 984 
 985 
Figure 10 Functional studies of novel genes. (a-c). Expression of (a) AQP1, (b) ATP13A3 986 
and (c) SOX17 mRNA in human pulmonary artery smooth muscle cells, pulmonary artery 987 
endothelial cells and blood outgrowth endothelial cells (BOECs) (n=4 biological replicates of 988 
each). Relative expression of each transcript was normalised to three reference genes, 989 
ACTB, B2M and HPRT. (d) Proliferation of BOECs in 5% FBS over 6 days. Cells were 990 
transfected with DharmaFECT1 alone (DH1), siATP13A3 or non-targeting siRNA control 991 
(siCP) (e-f) Quantification of apoptosis in BOECs, defined as Annexin V+/PI- cells, in 992 
BOECs transfected with siATP13A3 or siCP in complex with DH1 followed by 24hr treatment 993 
with 0.1% FBS or 5% FBS (n=4 biological repeats). (f) Measurement of apoptosis via 994 
Caspase-Glo 3/7 activity measurements in BOECs transfected with siATP13A3 or siCP in 995 
complex with DH1, followed by 16hr treatment in 0.1% FBS or 5% FBS. Data are from a 996 
single experiment (n=4 wells) representative of 3 biological repeats. Data were analysed 997 
 
25 
using a One-way analysis of variance with post hoc Tukey’s test for multiple comparisons in 998 
d and f. Data were analysed using a repeated measures One-way analysis of variance with 999 
post hoc Tukey’s for multiple comparisons in e. *P<0.05, **P<0.01 within treatment groups. 1000 
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Q9H7F0|AT133_HUMAN      -----------PVDFQNVLEDFTKQGFRVIALAHRKLESKLTWHK--VQNISRDAIENNM 714
P05023|AT1A1_HUMAN      HGKEQPLDEELKDAFQNAYLELGGLGERVLGFCHLFLPDEQFPEGFQFDTDDVNFPIDNL 583
                                      ***.  ::   * **:.:.*  * .:   .   .:. . :   :*:
Q9H7F0|AT133_HUMAN      SFSVILEHFQDLVPKLMLHGTVFARMAPDQKTQLIEALQNVDYFVGMCGDGANDCGALKR 893
P05023|AT1A1_HUMAN      ------EQLDDIL--KYHTEIVFARTSPQQKLIIVEGCQRQGAIVAVTGDGVNDSPALKK 727
                              *:::*::        **** :*:**  ::*. *. . :*.: ***.**. ***:
Q9H7F0|AT133_HUMAN      QYFSVTLLYSILSNLGDFQFLFIDLAIILVVVFTMSLNPAWKELVAQRPPSG----LISG 1004
P05023|AT1A1_HUMAN      TPFLIFIIANIPLPLGTVTILCIDLGTDMVPAISLAYEQAESDIMKRQPRNPKTDKLVNE 847













P29972|AQP1_HUMAN      LTGNSLGRNDLADGVNSGQGLGIEIIGTLQLVLCVLATTDRR-RRDLGGSAPLAIGLSVA 177
Q5R819|AQP1_PONAB      LPGNSLGRNDLADGVNSGQGLGIEIIGTLQLVLCVLATTDRR-RRDLGGSAPLAIGLSVA 177
Q02013|AQP1_MOUSE      LVDNSLGRNDLAHGVNSGQGLGIEIIGTLQLVLCVLATTDRR-RRDLGGSAPLAIGLSVA 177
P29975|AQP1_RAT        LLENSLGRNDLARGVNSGQGLGIEIIGTLQLVLCVLATTDRR-RRDLGGSAPLAIGLSVA 177
Q6PQZ1|AQP1_PIG        LPGNSLGLNSLAPGVDSGQGLGIEIIGTLQLVLCVLATTDRR-RRDLGGSAPLAIGFSVA 179
Q9N2J4|AQP1_CANLF      LPDNSLGRNELAPGVNSGQGLGIEIIGTLQLVLCVLATTDRR-RRDLGGSGPLAIGLSVA 179
P47865|AQP1_BOVIN      LPDNSLGLNALAPGVNSGQGLGIEIIGTLQLVLCVLATTDRR-RRDLGGSGPLAIGFSVA 179
P56401|AQP1_SHEEP      LPDNSLGLNALAPGVNSGQGLGIEIIGTLQLVLCVLATTDRRRRRDLGDSGPLAIGFSVA 180
                       *  **** * ** **:************************** *****.*.*****:***
P29972|AQP1_HUMAN      LGHLLAIDYTGCGINPARSFGSAVITHNFSNHWIFWVGPFIGGALAVLIYDFILAPRSSD 237
Q5R819|AQP1_PONAB      LGHLLAIDYTGCGINPARSFGSAVITHNFSNHWIFWVGPFIGGALAVLIYDFILAPRSSD 237
Q02013|AQP1_MOUSE      LGHLLAIDYTGCGINPARSFGSAVLTRNFSNHWIFWVGPFIGGALAVLIYDFILAPRSSD 237
P29975|AQP1_RAT        LGHLLAIDYTGCGINPARSFGSAVLTRNFSNHWIFWVGPFIGSALAVLIYDFILAPRSSD 237
Q6PQZ1|AQP1_PIG        LGHLLAIDYTGCGINPARSFGSAVITHNFQDHWVFWVGPFIGGALAVLIYDFILAPRSSD 239
Q9N2J4|AQP1_CANLF      LGHLLAIDYTGCGINPARSFGSSVITHNFKDHWIFWVGPFIGGALAVLIYDFILAPRSSD 239
P47865|AQP1_BOVIN      LGHLLAIDYTGCGINPARSFGSSVITHNFQDHWIFWVGPFIGAALAVLIYDFILAPRSSD 239
P56401|AQP1_SHEEP      LGHLLAIDYTGCGINPARSFGSSVITHNFQDHWIFWVGPFIGAALAVLIYDFILAPRSSD 240





































P48431|SOX2_HUMAN!! ! !!SRGQRRKMAQENPKMHNSEISKRLGAEWKLLSETEKRPFIDEAKRLRALHMKEHPDYKYR 111
P57073|SOX8_HUMAN!! ! !!AQAARRKLADQYPHLHNAELSKTLGKLWRLLSESEKRPFVEEAERLRVQHKKDHPDYKYQ 172
Q9H6I2|SOX17_HUMAN! ! !!AKDERKRLAQQNPDLHNAELSKMLGKSWKALTLAEKRPFVEEAERLRVQHMQDHPNYKYR 138
P35713|SOX18_HUMAN! ! !!AKDERKRLAQQNPDLHNAVLSKMLGKAWKELNAAEKRPFVEEAERLRVQHLRDHPNYKYR 155! ! ! ! ! ! ! ! ! ! ! !!::!!*:::*:: *.:**: :** **!!*: *. :*****::**:***. * ::**:***:
P48431|SOX2_HUMAN!! ! !!PRRKTKTLMKKDKYTLPGGLLAPG---------------GNSMASGVGVGAGLGAGVNQR 156
P57073|SOX8_HUMAN!! ! !!PRRRKSAKAGH---SDSDSG----------AELGPHPGGGAVYKAEAGLGDGHHHGDHTG 219
Q9H6I2|SOX17_HUMAN! ! !!PRRRKQVKRLK---RVEGGFLH-GLAEPQAAALGPE--GGRVAMD--GLGLQFP---EQG 187
P35713|SOX18_HUMAN! ! !!PRRKKQARKAR---RLEPGLLLPGLAPPQPPP--------------------------EP 186! ! ! ! ! ! ! ! ! ! ! !!***:...!!!:!! ! !!.! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! ! !
P14859|PO2F1_HUMAN! ! !!LPQSQSTPK-RI---DTPSLEEPSDLEELEQFAKTFKQRRIKLGFTQGDVGLAMGKLYGN 319
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Pulmonary arterial hypertension (PAH) is a rare lung disorder characterised by narrowing and 1 
obliteration of small pulmonary arteries ultimately leading to right heart failure. Here, the authors 2 
sequence whole genomes of over 1000 PAH patients and identify likely causal variants in GDF2, 3 
ATP13A3, AQP1 and SOX17. 4 
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